United StatesÚltimas notícias

A selloff in chipmakers dragged down stocks on concerns over whether massive artificial-intelligence investments will justify lofty valuations. Julian Emanuel, Chief Equity & Quantitative Strategist at Evercore ISI, discusses his S&P 500 call amid recent volatility.

On this episode of Stock Movers: - Fiserv (FISV) is climbing as the Wall Street Journal reports big banks including JPMorgan Chase, Bank of America, Wells Fargo and PNC Financial Services Group have held preliminary discussions about a deal to acquire a network owned by the financial-technology company Fiserv. - Crinetics Pharmaceuticals (CRNC) is soaring after Vertex Pharmaceuticals agreed to buy Crinetics for $10 billion in cash to expand into endocrinology. - SpaceX (SPCX) is lower even though at least six brokers, including Morgan Stanley and Goldman Sachs, have started coverage of SpaceX with buy-equivalent ratings. SpaceX's addition to the Nasdaq 100 should provide considerable support to the stock, considering the number of funds that track the tech-heavy benchmark.

SkinHealth Systems (NASDAQ:SKIN) received new United States Food and Drug Administration clearance for its specialized SkinStylus SteriLock MicroSystem to improve the appearance of periorbital wrinkles in adult patients.

Amazon.com is looking to raise at least $25 billion from a US dollar bond sale, its latest funding push as the company ramps up investment in AI infrastructure. Robert Schiffman and Ed Ludlow have more on "Bloomberg Open Interest."

SpaceX joins the Nasdaq 100 Index Tuesday and many analysts are saying buy the stock. But Nicholas Owens of Morningstar has a sell rating and price target of $62. He says shares are overvalued. He speaks on "Bloomberg Surveillance."

Axsome Therapeutics (NASDAQ:AXSM) announced it dosed the first patient in its Phase 3 FOCUS-2 clinical trial evaluating solriamfetol as a potential treatment for children with attention deficit hyperactivity disorder.

Amazon.com (NASDAQ:AMZN) is looking to raise at least $25 billion through a U.S. dollar bond sale, according to Bloomberg News, as the company continues funding AI infrastructure investments.

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 data for TTI-109, a phosphate prodrug of STAT3 inhibitor TTI-101, including up to 60% reductions in STAT3-driven Th17, Tfh, and B cell populations.

Walmart (NASDAQ:WMT) announced extensive price rollbacks on seasonal food items, including ground beef, sodas, and fresh produce to help consumers combat persistent grocery inflation pressures.

Julian Emanuel, Evercore ISI chief equity and quantitative strategist, doesn't believe the Federal Reserve will move on interest rates this year. Emanuel is maintaining his S&P 500 year-end price target of 7,750 even though stocks have become more volatile. He speaks on "Bloomberg Surveillance."

Lumen Technologies (NYSE:LUMN) completed its $475 million acquisition of Alkira, an on-demand networking platform that helps enterprises connect clouds, sites, partners, and AI workloads.

Samsung Electronics fell 6.92% in South Korea after forecasting a 19-fold jump in second-quarter operating profit to ₩89.4 trillion, pressuring chip stocks across global markets.